Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact.

Archive ouverte

Roussel, Benoit, D | Macrez, Richard | Jullienne, Amandine | Agin, Véronique | Maubert, Eric | Dauphinot, Luce | Potier, Marie-Claude | Plawinski, Laurent | Castel, Hervé | Hommet, Yannick | Munuera, Josep | Montaner, Joan | Yepes, Manuel | Ali, Carine | Vivien, Denis

Edité par CCSD ; Oxford University Press -

International audience. Recombinant tissue-type plasminogen activator (tPA) is the fibrinolytic drug of choice to treat stroke patients. However, a growing body of evidence indicates that besides its beneficial thrombolytic role, tPA can also have a deleterious effect on the ischaemic brain. Although ageing influences stroke incidence, complications and outcome, age-dependent relationships between endogenous tPA and stroke injuries have not been investigated yet. Here, we report that ageing is associated with a selective lowering of brain tPA expression in the murine brain. Moreover, our results show that albumin D site-binding protein (DBP) as a key age-associated regulator of the neuronal transcription of tPA. Additionally, inhibition of DBP-mediated tPA expression confers in vitro neuroprotection. Accordingly, reduced levels of tPA in old mice are associated with smaller excitotoxic/ischaemic injuries and protection of the permeability of the neurovascular unit during cerebral ischaemia. Likewise, we provide neuroradiological evidence indicating the existence of an inverse relationship between age and the volume of the ischaemic lesion in patients with acute ischaemic stroke. Together, these results indicate that the relationship among DBP, tPA and ageing play an important role in the outcome of cerebral ischaemia.

Suggestions

Du même auteur

Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic

Archive ouverte | Yepes, Manuel | CCSD

International audience. Thrombolysis with tissue-type plasminogen activator (tPA) is used for the treatment of patients with acute ischemic stroke. However, a growing body of evidence indicates that, besides the unq...

PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAalpha1) prevents the passage of tissue-type plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity.

Archive ouverte | Roussel, Benoit, D | CCSD

International audience. -

HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator.

Archive ouverte | Roussel, Benoit, D | CCSD

International audience. Owing to its ability to generate the clot-dissolving protease plasmin, tissue plasminogen activator (tPA) is the only approved drug for the acute treatment of ischemic stroke. However, tPA al...

Chargement des enrichissements...